An Open-label, Multi-centre Post-marketing Study to Assess the Efficacy and Safety of Voncento in Subjects with Von Willebrand Disease

Trial Profile

An Open-label, Multi-centre Post-marketing Study to Assess the Efficacy and Safety of Voncento in Subjects with Von Willebrand Disease

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 28 Aug 2017

At a glance

  • Drugs Von Willebrand factor (Primary)
  • Indications Von Willebrand disease
  • Focus Therapeutic Use
  • Sponsors CSL Behring
  • Most Recent Events

    • 19 Aug 2017 Planned End Date changed from 1 Feb 2018 to 15 Feb 2018.
    • 16 Aug 2017 Planned primary completion date changed from 1 Feb 2018 to 15 Feb 2018.
    • 10 Jun 2017 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top